3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
15
Lymphoma, B-Cell, Marginal Zone
5
Neoplasms, Plasma Cell
3
Lymphoma
3
Recurrence
2
Pseudomyxoma Peritonei
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Infections
1
Helicobacter Infections
1
Chemotherapy Effect
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Cachexia
1
Appendiceal Neoplasms
1
Interventions
Cyclophosphamide
10
ofatumumab
8
fludarabine
6
Rituximab
5
fludarabine phosphate
4
Bendamustine Hydrochloride
4
venetoclax
3
obinutuzumab
3
ibrutinib
3
acalabrutinib
3
Melphalan
3
pirtobrutinib
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Lenalidomide
2
Immunotherapy, Adoptive
2
Busulfan
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
pomalidomide
1
pivalyloxymethyl butyrate
1
pegaspargase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, B-Cell
×
Clarithromycin
×
Clear all
NCT01279252
2019-01-25
CLEAR
King's College Hospital NHS Trust
Phase 2
Completed
71 enrolled